Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 5/20 | 0.68 |
| ▸ | CCND1 | P24385 | 5/20 | 0.68 |
| ▸ | CCND2 | P30279 | 5/20 | 0.68 |
| ▸ | CCND3 | P30281 | 5/20 | 0.68 |
| ▸ | WEE1 | P30291 | 5/20 | 0.56 |
| ▸ | SRC | P12931 | 3/20 | 0.56 |
| ▸ | RIPK2 | O43353 | 10/20 | 0.52 |
| ▸ | NOD2 | Q9HC29 | 10/20 | 0.52 |
| ▸ | ACVR1 | Q04771 | 8/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | PAK4 | O96013 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5264440 | 0.81 | CDK4 (1.00) | CDK4CCND1CCND2CCND3WEE1 | |
| SCHEMBL3971273 | 0.80 | CDK4 (0.63) | CDK4CCND1CCND2CCND3WEE1 | |
| SCHEMBL3965253 | 0.79 | CDK4 (0.62) | CDK4CCND1CCND2CCND3WEE1 | |
| SCHEMBL3970927 | 0.74 | CDK4 (0.66) | CDK4CCND1CCND2CCND3WEE1 | |
| SCHEMBL4353287 | 0.73 | CDK4 (1.00) | CDK4CCND1CCND2CCND3SRC | |
| Hydrochloric Acid SCHEMBL30241083 | 0.73 | CDK4 (0.78) | CDK4CCND1CCND2CCND3WEE1 | |
| SCHEMBL5262387 | 0.70 | CDK4 (0.73) | CDK4CCND1CCND2CCND3WEE1 | |
| SCHEMBL5263497 | 0.70 | CDK4 (0.93) | CDK4CCND1CCND2CCND3WEE1 | |
| SCHEMBL6625830 | 0.70 | LCK (0.70) | CDK4CCND1CCND2CCND3WEE1 | |
| SCHEMBL22343717 | 0.70 | EGFR (0.57) | CDK4CCND1CCND2CCND3RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | claimed |
| EP-1080092-B1 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2008-07-23 | — | — | EP | claimed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | claimed |
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1080092-B1 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | DOBRUSIN ELLEN MYRA (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | CCNI, CCNH, CCNA1 | CDK4 4/4885CCND1 13/4885CCND2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.